esyd iso
English (United Kingdom)Ελληνικά

Home Services Research Lung Ca project
Lung Ca project PDF Print E-mail
Thursday, 10 October 2013 13:23


 The role of minor fibril-forming collagens on non-small cell lung cancer progression and metastasis



        Non-small cell lung cancer (NSCLC) represents a common and increasing cause of death in both genders. The main reason for the increased mortality from NSCLC is the inability of its early diagnosis. The NSCLC can be treated surgically in its early stages, and this underlines the need to develop a simple, reliable and cheap molecular marker for the detection of NSCLC in the beginning of carcinogenesis in the lung. The ECM of the lung represent an important constituent and it has been proposed that changes in the ECM of the lung may play a significant role in carcinogenesis. Experimental data have shown that collagen XI alpha-1 is overexpressed in NSCLC and especially in the adenocarcinoma of the lung and the levels of collagen XI alpha-1 have been correlated with the possibility of metastasis.


       The extracellular matrix (ECM) of the lung contains high amounts of various types of collagens and elastin. Collagens type I and III are known as major fibril-forming collagens, they are the most abundant collagens in the ECM of the lung and they are responsible for its tensile strength and elasticity. Under normal conditions collagens type I and III are forming heterotypic fibrils with collagen type V. Collagen type V is characterized as minor fibril-forming collagen, it is expressed in small amounts in the ECM, but plays a critical role in the regulation of the size/diameter of the heterotypic fibrils. Greater proportions of collagen type V have been shown to significantly decrease the diameter of the heterotypic fibrils, and in turn decrease tensile strength; however, other minor fibril-forming collagens may also be involved. One of these collagens is collagen XI alpha-1. Collagen XI alpha-1 is closely related to collagen type V structurally and biologically and previous studies have shown that collagen type XI alpha-1 and collagen type V have the same large globular amino-terminal domain with similar structure and size. It has been described that chains of collagen type XI alpha-1 can be combined with chains of collagen type V forming heteromeric collagen V/XI, especially in tissues other than cartilage. For this reason the minor fibril-forming collagens V and XI have been characterized as a subfamily of collagens, which are expressed in small amounts in the ECM, but they have a crucial role in controlling the size/diameter of heterotypic collagen fibrils. More specifically, the large globular amino-terminal domain has been suggested as a possible mechanism for the reduction of the tensile strength. This reduction occurs through steric hindrance between the large globular amino- terminal domain and the major fibril-forming collagens preventing their assembly into the heterotypic fibrils. Besides this molecular mechanism, which controls the thickness of major fibril-forming collagens, there is also at least one more mechanism, which can act independently or in concert with the mechanism of steric hindrance to control the size/diameter of heterotypic fibrils. Detailed proteomic analysis of the large globular amino-terminal domains of collagen type V and XI alpha-1 has shown that these domains contain a well-characterized heparine binding domain (HBD). It is also known from other studies that the HBD can interact with various receptors in the ECM. For example an increased synthesis and activation of matrix metalloproteases can be occurred through the activation of integrin receptors alpha-4 beta-1 from HBD, which in turn can lead to increased degradation of the ECM.



 Aim of the study


           In the present study we plan to determine the gene expression differences, at both the mRNA and protein level, of all fibril-forming collagens and their specific integrin receptors in surgical specimens from patients with NSCLC and to compare these results with normal lung. In addition, we plan to detect and correlate any changes at the mRNA level of fibril-forming collagens in the corresponding patients’ peripheral blood. The quantification of these macromolecules may represent novel biomarkers for the detection of the stage of this type of cancer, as well as for prognosis determination.





          Clinical and demographic data will be collected from all patients. Surgical samples will be collected from the removed lung specimens of the pathologic groups [IA, IB, IIA, IIB, IIIA, IIIB, IV] at the site of tumor and distal to the lesion (internal controls). External controls will come from patients who undergo lung resections for benign diseases of the lung. Peripheral blood samples from the corresponding patients will be also collected. One sample will be collected preoperatively and one sample will be collected 1 month postoperatively.

          Histologic analysis, immunohistochemistry, immunofluorescence, quantitative real-time RT-PCR and Western blot analysis will be performed for the detection and quantification of fibril-forming collagens and specific integrin receptors.




Expected results


         We hypothesize that alterations in expression levels and synthesis of specific fibril-forming collagens occur during the remodeling of the ECM in the lung in non-small cell lung cancer (NSCLC) in order to facilitate metastasis. The regulatory role of minor fibril-forming collagens type V and XI alpha-1 may be crucial in these pathologic conditions and may represent a novel common molecular mechanism for the control of the thickness and characteristics of the ECM. We have already shown that in NSCLC there was a statistically significant increased expression of the mRNA levels of collagen type V alpha-2 and all isoforms of collagen XI alpha-1 when compared with normal lung. In addition, there was a gradually increase of the mRNA levels of collagen type V alpha-2 and all isoforms of collagen XI alpha-1, in parallel with the increase of the pathologic stage from IB to IV.






1.       Dunsmore SE, Rannels DE. Extracellular matrix biology in the lung. Am J Physiol 1996;270(1 Pt 1):L3-27.


2.       Gelse K, Poschl E, Aigner T. Collagens--structure, function, and biosynthesis. Adv Drug Deliv Rev 2003;55(12):1531-1546.


3.       Birk DE. Type V collagen: heterotypic type I/V collagen interactions in the regulation of fibril assembly. Micron 2001;32(3):223-237.


4.       Kadler KE, Hill A, Canty-Laird EG. Collagen fibrillogenesis: fibronectin, integrins, and minor collagens as organizers and nucleators. Curr Opin Cell Biol 2008;20(5):495-501.


5.       Wenstrup RJ, Florer JB, Brunskill EW, Bell SM, Chervoneva I, Birk DE. Type V collagen controls the initiation of collagen fibril assembly. J Biol Chem 2004;279(51):53331-53337.


6.       Adachi E, Hayashi T. In vitro formation of hybrid fibrils of type V collagen and type I collagen. Limited growth of type I collagen into thick fibrils by type V collagen. Connect Tissue Res 1986;14(4):257-266.


7.       Hansen U, Bruckner P. Macromolecular specificity of collagen fibrillogenesis: fibrils of collagens I and XI contain a heterotypic alloyed core and a collagen I sheath. J Biol Chem 2003;278(39):37352-37359.


8.       Lui VC, Kong RY, Nicholls J, Cheung AN, Cheah KS. The mRNAs for the three chains of human collagen type XI are widely distributed but not necessarily co-expressed: implications for homotrimeric, heterotrimeric and heterotypic collagen molecules. Biochem J 1995;311 ( Pt 2):511-516.


9.       Fallahi A, Kroll B, Warner LR et al. Structural model of the amino propeptide of collagen XI alpha1 chain with similarity to the LNS domains. Protein Sci 2005;14(6):1526-1537.


10.     Unsold C, Pappano WN, Imamura Y, Steiglitz BM, Greenspan DS. Biosynthetic processing of the pro-alpha 1(V)2pro-alpha 2(V) collagen heterotrimer by bone morphogenetic protein-1 and furin-like proprotein convertases. J Biol Chem 2002;277(7):5596-5602.


11.     Elzie CA, Murphy-Ullrich JE. The N-terminus of thrombospondin: the domain stands apart. Int J Biochem Cell Biol 2004;36(6):1090-1101.


12.     Leitinger B, Hohenester E. Mammalian collagen receptors. Matrix Biol 2007;26(3):146-155.


13.     Gregory KE, Oxford JT, Chen Y et al. Structural organization of distinct domains within the non-collagenous N-terminal region of collagen type XI. J Biol Chem 2000;275(15):11498-11506.


14.     Oxford JT, DeScala J, Morris N et al. Interaction between amino propeptides of type XI procollagen alpha1 chains. J Biol Chem 2004;279(12):10939-10945.


15.     Rousseau JC, Farjanel J, Boutillon MM, Hartmann DJ, van der RM, Moradi-Ameli M. Processing of type XI collagen. Determination of the matrix forms of the alpha1(XI) chain. J Biol Chem 1996;271(39):23743-23748.


16.     Warner LR, Brown RJ, Yingst SM, Oxford JT. Isoform-specific heparan sulfate binding within the amino-terminal noncollagenous domain of collagen alpha1(XI). J Biol Chem 2006;281(51):39507-39516.


17.     Warner LR, Blasick CM, Brown RJ, Oxford JT. Expression, purification, and refolding of recombinant collagen alpha1(XI) amino terminal domain splice variants. Protein Expr Purif 2007;52(2):403-409.


18.     Medeck RJ, Sosa S, Morris N, Oxford JT. BMP-1-mediated proteolytic processing of alternatively spliced isoforms of collagen type XI. Biochem J 2003;376(Pt 2):361-368.


19.     Alberg AJ, Ford JG, Samet JM. Epidemiology of lung cancer: ACCP evidence-based clinical practice guidelines (2nd edition). Chest 2007;132(3 Suppl):29S-55S.


20.     Han JY, Kim HS, Lee SH, Park WS, Lee JY, Yoo NJ. Immunohistochemical expression of integrins and extracellular matrix proteins in non-small cell lung cancer: correlation with lymph node metastasis. Lung Cancer 2003;41(1):65-70.


21.     Yang X, Sun X. Meta-analysis of several gene lists for distinct types of cancer: a simple way to reveal common prognostic markers. BMC Bioinformatics 2007;8:118.


22.     Chong IW, Chang MY, Chang HC et al. Great potential of a panel of multiple hMTH1, SPD, ITGA11 and COL11A1 markers for diagnosis of patients with non-small cell lung cancer. Oncol Rep 2006;16(5):981-988.


23.     Wang KK, Liu N, Radulovich N et al. Novel candidate tumor marker genes for lung adenocarcinoma. Oncogene 2002;21(49):7598-7604.


24.     Toumpoulis IK, Chamogeorgakis TP, Nikolopoulos SN. Differential gene expression of collagen type alpha-2(V) and alpha-1(XI) in patients with non-small cell lung cancer. 1st International Conference on Molecular Cancer Research 2009, November 27-29, Athens, Greece.



The role of minor fibril-forming collagens on non-small cell lung cancer progression and metastasis



The role of minor fibril-forming collagens on non-small cell lung cancer progression and metastasis




Image of the day



Developed by LiquidMinds | Powered by | Valid XHTML | Valid CSS.